However, there were no enrichment of genome sets involving immune-related activities and typical tumor pathways in the high SLC13A4 expression group, which further suggested that low SLC13A4 expression might be implicated in the process of cancer development and immune activities. The gene discussed is SLC13A4; the disease is cancer.